The DiaPat® test allows diagnosis of diseases from a urine sample in early stages before organ damages become manifest.
The principle of this diagnostic approach is based on the fact that proteins are indispensable for the function of cells and organs. Thousands of proteins and peptides are involved, forming a diagnostic pattern that changes with the onset and progression of a disease. The DiaPat® technology identifies up to 6,000 of these proteins and polypeptides and subsequently generates disease specific patterns.
DiaPat®-based precise monitoring of diseases enables individualized therapeutic intervention. The early initiation of therapy can delay disease progression or even lead to total remission. Hence, the modern and reliable diagnostic approach cannot only safe lives, but also increase quality of life.
The DiaPat® method was applied in 60 clinical trials leading to more than 155 publications in high ranking peer-reviewed scientific journals. These trials revealed the reliability of the diagnostic approach resulting in highly beneficial outcomes for patients suffering e.g. from chronic renal diseases, coronary artery disease or urogenital cancers. The analytical platform was approved by U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).